Keene & Associates Inc. Has $851,000 Stake in Haemonetics Co. (NYSE:HAE)

Keene & Associates Inc. lifted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 7.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,904 shares of the medical instruments supplier’s stock after purchasing an additional 730 shares during the quarter. Keene & Associates Inc.’s holdings in Haemonetics were worth $851,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Vontobel Holding Ltd. increased its stake in Haemonetics by 3.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier’s stock worth $392,000 after purchasing an additional 180 shares in the last quarter. Versor Investments LP boosted its holdings in shares of Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier’s stock valued at $289,000 after buying an additional 300 shares during the period. First Personal Financial Services increased its position in shares of Haemonetics by 2.9% during the third quarter. First Personal Financial Services now owns 11,110 shares of the medical instruments supplier’s stock worth $893,000 after acquiring an additional 312 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of Haemonetics by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 5,880 shares of the medical instruments supplier’s stock worth $472,000 after acquiring an additional 400 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its position in Haemonetics by 0.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier’s stock valued at $5,033,000 after acquiring an additional 407 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

NYSE HAE opened at $64.14 on Wednesday. The firm has a market capitalization of $3.22 billion, a P/E ratio of 25.25, a price-to-earnings-growth ratio of 1.09 and a beta of 0.39. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm’s fifty day moving average price is $73.77 and its two-hundred day moving average price is $77.03. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on HAE shares. Raymond James reissued a “strong-buy” rating and issued a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research decreased their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Finally, JMP Securities reduced their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.